ClinicalTrials.gg
CompletedNCT01518907Updated Mar 19, 2015

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

A Phase 1 interventional study of COLLAGENASE CLOSTRIDIUM HISTOLYTICUM in Edematous Fibrosclerotic Panniculopathy and Cellulite, sponsored by Endo Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-03-19.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
21 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.

Enrollment
9th of 15
99 · median 150
Started
2012
the only one that year
Phase 1
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
14 of 15
Endo Pharmaceuticals

Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 1, and was the 1st registered.

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

Browse Cellulite studies →

Open to participants now

None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →

Where they have run

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 21 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Microbial Collagenase in Cellulite as a file.
02

Study summary

This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.

03

Conditions studied

  • Edematous Fibrosclerotic Panniculopathy
  • Cellulite

Browse trials for

Keywords

  • cellulite
  • Xiaflex
04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a female and be ≥ 21 years of age and ≤ 60 years of age
  • Have a skin type classification of I through V according to the Fitzpatrick scale
  • Have EFP within the posterolateral thigh(s) and/or buttock(s) for at least 12 months before the screening visit
  • Have a photonumeric cellulite severity scale (CSS) score of ≥ 7 representing moderate to severe cellulite severity within the right or left buttock or the right or left posterolateral thigh (selected quadrant)
  • Have an area of EFP within the selected quadrant that is at least 8 cm x 10 cm (ie, target EFP area) and is suitable for treatment:

    • The target EFP area must be located on the posterolateral thigh or within the buttock and does not involve the gluteal fold
    • The target EFP area must be evident when the subject is standing, without the use of any manipulation such as skin pinching or muscle contraction (ie, CSS Classification E score of 2 or 3) at screening and before injection
  • Have a (BMI) between 20.0 and 33.0 kg/m2, and intends to maintain stable body weight throughout the duration of the study (a variation of ≤5% from baseline body weight is permitted)
  • Be willing to refrain from using artificial tanning devices and lotions during the 2-week period before screening and throughout the duration of the study
  • Be willing to apply sunscreen with sun protection factor (SPF) ≥15 to the selected quadrant before each exposure to the sun while participating in the study (ie, screening through Day 90)
  • Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening
  • Have a negative urine pregnancy test at screening and before injection of AA4500 and be using an effective method (ie, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study, or be surgically sterile, or be a female (no menses for at least 1 year or hysterectomy)
  • Be willing and able to cooperate with the requirements of the study including requirements during the confinement period and throughout the study
  • Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee (IRB/IEC/HREC). The subject must also sign an authorization form to allow disclosure of her protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution
  • Be able to complete and understand the various rating instruments in English

Exclusion criteria

Exclusion Criteria:

  • Has any of the following conditions:

    • Thyroid disease, unless controlled with medication for ≥ 6 months
    • Uncontrolled diabetes mellitus, as determined by the investigator
    • Uncontrolled hypertension, as determined by the investigator
    • Vascular disorder (eg, phlebitis or varicose veins) in area to be treated
    • Lipedema or a lymphatic disorder
    • History of lower extremity thrombosis or post-thrombosis syndrome
    • Documented disorder such as lupus erythematosus, rheumatoid arthritis
    • Inflammation or active infection in area to be treated
    • Cutaneous alteration in area to be treated
    • Rash, eczema, psoriasis, or skin cancer in the area to be treated
    • History of keloidal scarring or abnormal wound healing
    • Coagulation disorder; taking an anticoagulant (except for ≤ 150 mg aspirin daily) up to 7 days prior to injection day
    • Known active or C (history of hepatitis A is permitted)
    • Known immune deficiency disease or a positive test for (HIV)
    • Other significant conditions including body dysmorphic disorder, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  • Has used any of the following for the treatment of EFP on the legs or buttock or intends to use any of the following at any time during the study:

    • Liposuction at any time before injection of AA4500
    • Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; or surgery (including subcision) within 12 months before injection of AA4500
    • Endermologie or similar treatments within 6 months before injection of AA4500
    • Massage therapy within 3 months before injection of AA4500
    • Creams to prevent or mitigate EFP within 2 weeks before injection of AA4500
  • Has a tattoo in the quadrant selected for treatment
  • Is presently nursing a baby or providing breast milk for a baby
  • Intends to become pregnant during the study
  • Intends to initiate an intensive sport or exercise program during the study
  • Has an unrealistic expectation for treatment outcome, as determined by the investigator
  • Has a positive alcohol breath test and/or a positive urine drug screen for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and/or propoxyphene at screening or Day -1
  • Has received an drug or treatment within 30 days before injection of AA4500
  • Has a known systemic allergy to collagenase or any other of AA4500
  • Has received any collagenase treatments within 30 days before treatment
  • Has, at any time, received AA4500
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    AA4500 0.0029 mg in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.0145 mg in 5 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.0145 mg in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.0435 mg in 5 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.0435 mg in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.116 mg in 5 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.116 mg in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.232 mg in 5 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 at 0.232 in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.464 mg in 5 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Experimental
    AA4500 0.464 mg in 1 mL

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator global aesthetic improvement scale assessment of the target cellulite area

    Time frame: Day 90

  2. Subject global aesthetic improvement scale assessment of the target cellulite area

    Time frame: Day 90

  3. A responder analysis based on proportion of subjects with a ≥ 30% improvement from baseline in the absolute surface depth of the central dimple/depression based on 3D digital photography.

    Time frame: Day 90

  4. Percent change from baseline in total absolute surface depth of the central dimple/depression based on 3D digital photography.

    Time frame: Day 90

07

Study locations

1 site
  • SNBL Clinical Pharmacology Center, Inc
    Baltimore, Maryland 21201, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Dec 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Jan 26, 2012
Start
Jan 2012
Primary completionActual
Dec 2012
CompletionActual
Feb 2013
Last update
Mar 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01518907
Responsible party
Sponsor
First posted
Jan 26, 2012
Start date
Jan 2012
Primary completion
Dec 2012
Completion
Feb 2013
Last update
Mar 19, 2015

Study contacts

Veronica Urdaneta, MD MPH
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion